New Ethical Thinking Is Needed for Artificial Intelligence–Based Cell and Drug Treatment for Patients Treated with Precision Oncology

Abstract

Introduction: Artificial Intelligence (AI) has emerged as a transformative tool in Precision Oncology (PO), offering advanced capabilities in personalized medicine, drug delivery, and treatment planning. The integration of AI in PO allows for the customization of therapies based on an individual patient’s genetic makeup, optimizing treatment efficacy while minimizing toxicity. However, despite these promising advancements, AI’s application in oncology also raises significant ethical and regulatory challenges. Patient privacy, autonomy, algorithmic bias, and equitable access to AI-driven healthcare remain pressing concerns. Additionally, regulatory frameworks struggle to keep pace with the rapid advancements in AI technologies. This paper explores the ethical implications and considerations associated with AI in PO, emphasizing the need for a balanced approach to technological innovation and ethical responsibility. Materials and Methods: This study reviews existing literature on AI applications in PO, focusing on ethical considerations and challenges. The methodology involves a comprehensive analysis of current AI-driven PO systems, including their benefits, risks, and ethical dilemmas. Various sources, including academic publications, ethical guidelines and case studies, were examined to provide an in-depth understanding of AI’s role in PO. The study categorizes ethical concerns into key areas such as patient privacy, data security, informed consent, algorithmic bias, and equitable access. Additionally, the research investigates regulatory frameworks across different countries, highlighting discrepancies and areas needing improvement. Results: The findings indicate that while AI has significantly enhanced diagnostic accuracy, treatment personalization, and clinical decision-making in PO, numerous ethical and challenges persist. Key results include: Patient Privacy and Data Security, AI-driven PO relies on extensive patient data, raising concerns about confidentiality and unauthorized access. Robust encryption and stringent data-sharing policies are necessary to mitigate risks. Algorithmic Bias, AI models trained on non-diverse datasets may lead to biased treatment recommendations, disproportionately affecting underrepresented populations. Informed Consent and Autonomy, Patients often lack awareness of how AI systems make treatment decisions, necessitating transparent consent procedures. Conclusion: AI presents a ground breaking opportunity to revolutionize PO by enabling more precise and effective treatments. However, ethical considerations must be addressed to ensure that AI-driven solutions uphold patient rights, prevent biases, and promote equitable healthcare access. Future advancements should prioritize patient-centric approaches, interdisciplinary collaboration, and proactive ethical adaptations. Strengthening ethical frameworks and standardizing AI governance can enhance the responsible use of AI in PO, ultimately improving cancer treatment outcomes while safeguarding patient welfare.

Ähnliche Arbeiten